| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| We have analyzed the expression of 12 protooncogenes , c Ha ras , c Ki ras , N ras , c myc , N myc , c fos , c abl , c fes , c fms , c raf , c erbB 1 , and c erbB 2 , in tissues of human renal cell carcinomas and in adjacent normal kidneys . ^^^ Significant elevations of expression were found in one of 16 cases of each for c Ha ras and c fms , whereas expression of c Ki ras , N myc , c fes , c abl , or c erbB 2 could not be detected in any of the tissues surveyed . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Southern blot analysis of 3T3 or Rat 2 transfectants carrying oncogenes from radiation transformed C3H / 10T1 / 2 or hamster cells indicates that the oncogenes responsible for the transformation of 3T3 cells are not the Ki ras , Ha ras , or N ras genes , nor are they neu , trk , raf , abl , or fms , although quick blot analysis using 11 oncogene probes detected increased transcripts of c abl and c fms in the 3T3 transformants containing oncogenic sequences from the 10 ray transformed C3H / 10T1 / 2 cells . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| The RNA was hybridized against 5 viral oncogene probes ( 5 jun , 5 myc , 5 erbB , 5 erbA and 5 fes ) , 6 human cellular oncogene probes ( N ras , c Blym 1 c erbB 2 , c fos , c myb and c abl ) , human p 53 tumor suppressor gene , and bovine LDH A gene probes . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Previous examinations with int 2 ( 11q13 ) and erbB 2 ( 17q11 . 2 13 ) were included for comparison . 1 FISH analysis detected a gain of 3q27 in 17 , of 5p15 . 2 in 7 , of c myc in 14 , of c abl in 10 , and formerly , of int 2 in 12 and of erbB 2 in 10 of the examined tumors . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| To this end , we have analyzed the protein expression of membrane associated epidermal growth factor receptor ( EGF R ) , Her 2 / neu , platelet derived growth factor receptor ( PDGF R ) , insulin like growth factor receptor ( IGF R ) , c Kit and of cytoplasmatic c Abl in 500 human tumors of epithelial , stromal and mesenchymal origin by immunohistochemistry , and found a distinct pattern of kinase expression : EGF R , PDGF R and c Abl were expressed in the majority of malignant tumors , whereas c Kit , Her 2 / neu and IGF R protein expression was considerably less frequent . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| In addition , these revertants also resisted transformation by neu and several additional oncogenes ( H ras , N ras , 5 mos , 5 abl , and 5 fos ) as determined by focus forming assays . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| A detailed analysis of the NIH 3T3 transformants generated from REC : myc : gamma 33 and gamma 41 DNA failed to detect Ha ras , Ki ras , raf , neu , trk , abl , fms , or src oncogenes of rat origin . ( ABSTRACT TRUNCATED AT 400 WORDS ) . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NRAS , MYCN , CSFIR , MYB , MYC , ABL , HRASI , TP 53 , and ERBB 2 did not reveal any consistent alterations in tumour DNA . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Over 40 distinct protein kinases contain Pro 10 ( Ser / Thr ) Pro sequences including the human receptors for insulin and epidermal growth factor , and kinases encoded by the human proto oncogenes abl , neu , and raf 1 , and Schizosaccharomyces pombe cell cycle control genes ran 1 and wee 1 . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Upon assaying the steady state levels of oncogene encoded transcripts in normal rat colon , we found that fos and N myc are highly expressed ; H ras , K ras , myc , myb , and neu messages are present at lower levels ; and N ras , abl , and raf mRNAs are absent . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Analysis of cellular oncogenes showed that myc and fps were amplified approximately tenfold and threefold , respectively , in this cell line , whereas N myc , L myc , N ras , K ras , H ras , abl , erbB 2 , Blym , src , raf 1 , myb , and sis were not changed significantly . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NIH3T3 transformants from a tertiary round of transfection were analysed by Southern blot analysis for the presence of Ki ras , N ras , raf , trk , abl , fms , src , mos , fos , sis , fps , erbA , erbB or neu oncogenes of REC origin , and none were detected . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Some oncogenes such as the ras , myc , erbB 2 and abl have been extensively investigated in the progression of carcinogenesis in several types of human tumors . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| ErbB 1 , erbB 2 and abl oncogenes encoding tyrosine kinases , ras oncogenes encoding GTP binding proteins and myc oncogenes whose functions are not well understood are some examples . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Immunoblotting identified two peripheral membrane tyrosine kinases , p6O ( src ) and p 120 ( abl ) , stably associated with the p 185 ( neu ) containing signal transduction particle . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| We identified 30 tyrosine kinases expressed in these tissues : they include 10 non receptor tyrosine kinases ( yes , fyn , lyn , brk , abl , arg , jak 1 , jak 3 , tyk 2 and itk ) , 17 receptor tyrosine kinases ( erbB 2 , PDGF Ralpha , PDGF Rbeta , kit , c fms , met , ron , FGF R 1 , FGF R 2 , FGF R 3 , FGF R 4 , cek 5 , tie 1 , tkt , axl , sky and Ins R ) , 2 dual kinases ( mek and sek ) and one possible novel kinase . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Examples of new agents are : trastuzumab ( Herceptin ) , a humanized monoclonal antibody that blocks the HER 2 / neu proto oncogene in combination with cytotoxic agents , is used in a percentage of breast cancer patients ; signal transduction inhibitor of abl tyrosine kinase STI 571 ( Glivec ) has been shown to be an active treatment for chronic myeloid leukemia and GISTs ; epidermal growth factor receptors in certain tumors have been targeted with agents such as C 225 ( Cetuximab ) and ZD 1839 ( IRESSA ) ; an adenosine deaminase analogue of deoxyadenosine , Cladribine ( 2 chloro 2 deoxy adenosine ) has shown high effectiveness in hairy cell leukemia and the multitargeted antifolate ( Premetrexed ) and several vaccines have been studied and are in clinical trials for resistant cancers . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| On the other hand , trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity . 1 will contrast below aspects in the development of inhibitors of Abl , c Kit , HER2 / neu ( erbB 2 ) , and EGFR , highlight successes and pitfalls in this field , and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer . . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Immunohistochemical analysis for estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER 2 / neu , C kit , Abl , and PDGFR beta expression were performed . ^^^ HER 2 / Neu , Abl , or PDGFR beta expression may be of value in order to investigate novel multimodality treatment strategies . . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| We will contrast lessons derived from the development of inhibitors of Abl , c Kit , HER2 / neu ( erbB 2 ) , and EGFR , highlight successes and limitations in the field , and propose new approaches for clinical development of tyrosine kinase inhibitor therapy . . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| Peptidomimetic ligands based on the sequence of target proteins for SH 2 and SH 3 domains may represent new lead compounds for the therapy of proliferative diseases that are dependent upon constitutively activated tyrosine kinases ( e . g . , BCR / ABL in chronic myelogenous and acute lymphocytic leukemias or HER 2 / Neu in breast and ovarian cancer . . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| The activation of Akt by transforming mutations , such as the amplification of HER 2 / neu in breast cancer and the formation of the BCR / ABL fusion gene in chronic myelogenous leukemia , seems to be essential for the transforming activity of these oncogenes . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| This assumption has been derived by the successful development of BCR / ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD 20 monoclonal antibodies in lymphoproliferative disease and of anti HER 2 agents in breast tumors overexpressing the targeted antigens . ^^^ |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00519 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|